FDA-approved Therapies for Geographic Atrophy

Opinion
Video

An expert retina specialist discusses the recent FDA-approved treatments for geographic atrophy (GA) that slow disease progression and highlights key factors to consider before starting treatment.

Recent Videos
2 experts are featured in this series.
Related Content
Ocugen, Inc. completes dosing in Phase 2 portion of ArMaDa clinical trial for OCU410

Ocugen, Inc. completes dosing in Phase 2 portion of ArMaDa clinical trial for OCU410

Sydney M Crago
February 19th 2025
Article
Spotlighting telemedicine in the year of a pandemic

Spotlighting telemedicine in the year of a pandemic

Alex Delaney-Gesing
October 19th 2020
Podcast
FDA approves amended label for Izervay for geographic atrophy

FDA approves amended label for Izervay for geographic atrophy

Emily Kaiser Maharjan
February 13th 2025
Article
SeaBeLife announces preclinical efficacy results for SBL03 topical ophthalmic gel

SeaBeLife announces preclinical efficacy results for SBL03 topical ophthalmic gel

Hattie Hayes
January 30th 2025
Article
A study of the 3-year clinical outcomes in geographic atrophy

A study of the 3-year clinical outcomes in geographic atrophy

Lynda Charters
January 28th 2025
Article
Apellis Pharmaceuticals receives approval of pegcetacoplan (Syfovre) for treatment of geographic atrophy in Australia

Apellis Pharmaceuticals receives approval of pegcetacoplan (Syfovre) for treatment of geographic atrophy in Australia

Martin David Harp
January 28th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.